Bytes Technology Group plc (BYITY)

Revance Therapeutics Cash Flow Statement

Financials in millions GBP. Fiscal year is March - February.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb 28, 2025	Feb 29, 2024	Feb 28, 2023	Feb 28, 2022	Feb 28, 2021
Net Income	54.84	46.85	40.42	32.85	19.93
Depreciation & Amortization	2.43	2.22	2.41	2.58	2.64
Other Amortization	0.21	0.16	0.07	0.03	0.04
Loss (Gain) From Sale of Assets	-	-	0	0.02	0.02
Loss (Gain) on Equity Investments	0.01	-0.17	-	-	-
Stock-Based Compensation	5.05	5.71	4.19	2.56	0.96
Other Operating Activities	0.91	-0.3	-0.28	-0.37	-3.41
Change in Accounts Receivable	-43.94	-39.26	-32.68	-50.27	-30.82
Change in Inventory	0.05	-0	0.04	0.5	0.1
Change in Accounts Payable	49.62	46.2	14.11	60.49	40.61
Change in Unearned Revenue	5.79	-4.41	9.87	3.66	1.16
Operating Cash Flow	74.97	57.01	38.15	52.05	31.22
Operating Cash Flow Growth	31.51%	49.42%	-26.70%	66.70%	-15.78%
Capital Expenditures	-6.36	-1.09	-1.09	-0.5	-0.61
Sale (Purchase) of Intangibles	-3.71	-0.25	-0.27	-0.12	-
Investment in Securities	-	-3.03	-	-	-
Other Investing Activities	-	-	-	-	-16.68
Investing Cash Flow	-10.07	-4.36	-1.36	-0.62	-17.28
Long-Term Debt Repaid	-0.61	-0.21	-0.23	-0.26	-0.3
Net Debt Issued (Repaid)	-0.61	-0.21	-0.23	-0.26	-0.3
Issuance of Common Stock	2.79	0.02	-	-	8.33
Common Dividends Paid	-21.91	-18.68	-15.81	-4.79	-48.6
Financing Cash Flow	-40.66	-36.83	-30.89	-5.05	-40.56
Net Cash Flow	24.24	15.82	5.9	46.38	-26.62
Free Cash Flow	68.61	55.92	37.06	51.55	30.62
Free Cash Flow Growth	22.69%	50.90%	-28.12%	68.39%	-13.33%
Free Cash Flow Margin	31.60%	27.01%	20.09%	35.35%	7.78%
Free Cash Flow Per Share	0.28	0.23	0.15	0.21	0.13
Cash Interest Paid	0.22	0.33	0.44	0.53	0.12
Cash Income Tax Paid	18.93	15.11	10.3	9.14	10.21
Levered Free Cash Flow	49.86	46.82	28.18	45.22	13.95
Unlevered Free Cash Flow	50.04	47.07	28.49	45.59	14.07
Change in Net Working Capital	-10.9	-4.87	8.62	-14.69	10.78

Source: S&P Global Market Intelligence. Standard template. Financial Sources.